BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

BioMachines Announces European Distributor For Its Products


5/2/2006 10:06:39 AM

RESEARCH TRIANGLE PARK, N.C., May 1 /PRNewswire/ -- BioMachines Inc., a biotech company that develops, manufactures and sells advanced automation tools to accelerate drug discovery, today announced the signing of a distribution agreement with Disruptive Technologies of Paris, France. With the signing of this agreement, BioMachines has expanded its sales channel beyond North America and into Western Europe.

"Europe is a very large market and there is a demand for our products", said Tom Larrichio, BioMachines' Chief Executive Officer. "We are very pleased to have found a company like Disruptive Technologies, whose principals have deep knowledge and understanding of the proteomics and genomics market in Europe -- they will serve us well," said Larrichio.

"We are very pleased to have signed this distribution agreement with a very innovative partner such as BioMachines," said Franck Do Vale, Disruptive Technologies' Technical Director and Co-Founder of the company.

"Thanks to BioMachines' unique product line, research scientists in the genomics and proteomics market will increase their productivity through complete automation of mission critical processes," said William Amoyal, Disruptive Technologies' Sales and Marketing Director and Co-Founder of the company.

About BioMachines Inc.

BioMachines Inc., a privately owned biotech company, provides the life sciences industry with proven solutions for drug discovery through advanced automation. Its vision-enabled, small-liquid, high-precision instrument systems are designed to automate complex laboratory workflows. Current products focus on automating front-end sample preparation for MALDI (Matrix- assisted laser desorption/ionization) mass spectrometry analysis. BioMachines' instrumentation and consumable platform provides cost-effective, reliable and high-quality solutions that scale from discovery in the research laboratory to clinical drug development. BioMachines is headquartered in Research Triangle Park, North Carolina. For more information, please visit www.bio-machines.com.

About Disruptive Technologies

Based in the Paris, France area, Disruptive Technologies, distributes a range of scientific instruments, consumables and software to increase the productivity of the scientists in the pharmaceutical, chemical, food and agricultural industries and reduce the overall cost of research. These solutions include sample preparation, separation, detection, imaging and dissolution techniques. Detailed information about the company and product lines are available at www.disruptechno.com.

BioMachines Inc.

CONTACT: Lucas Rugani of BioMachines Inc., +1-919-883-0013, orlrugani@bio-machines.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES